Bergen Brunswig to focus on supply channel cost-management strategies after calling off Ivax merger.
This article was originally published in The Gray Sheet
Executive Summary
BERGEN SUPPLY EFFICIENCIES REMAIN "CENTRAL STRATEGY" AFTER COLLAPSE OF IVAX MERGER agreement, the pharmaceutical and medical/surgical product distributor said in a March 20 release. "One of Bergen Brunswig's central strategies is to pursue opportunities to manage supply channel costs" through in-house programs, alliances or acquisitions, Bergen said.